Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.54 |
| ▸ | GSR | P00390 | 1/20 | 0.47 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.44 |
| ▸ | ARG2 | P78540 | 4/20 | 0.43 |
| ▸ | ARG1 | P05089 | 3/20 | 0.43 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.43 |
| ▸ | NOS2 | P35228 | 5/20 | 0.42 |
| ▸ | NOS1 | P29475 | 3/20 | 0.42 |
| ▸ | NOS3 | P29474 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1059272 | 1.00 | OTC (0.54) | OTCGSRDDAH1ARG2ARG1 | |
| SCHEMBL2263926 | 0.88 | OTC (0.46) | OTCGSRDDAH1NOD1NOS2 | |
| SCHEMBL2263934 | 0.88 | OTC (0.46) | OTCGSRDDAH1NOD1NOS2 | |
| SCHEMBL5974000 | 0.81 | OTC (0.58) | OTCGSRDDAH1ARG2ARG1 | |
| SCHEMBL18350239 | 0.81 | OTC (0.58) | OTCGSRDDAH1ARG2ARG1 | |
| SCHEMBL12801966 | 0.81 | OTC (0.58) | OTCGSRDDAH1ARG2ARG1 | |
| SCHEMBL14682811 | 0.81 | OTC (0.58) | OTCGSRDDAH1ARG2ARG1 | |
| SCHEMBL6672850 | 0.81 | OTC (0.58) | OTCGSRDDAH1ARG2ARG1 | |
| SCHEMBL5973446 | 0.81 | OTC (0.58) | OTCGSRDDAH1ARG2ARG1 | |
| SCHEMBL6183879 | 0.81 | OTC (0.58) | OTCGSRDDAH1ARG2ARG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3146977-B1 | TFPI INHIBITORS AND METHODS OF USE | TAKEDA PHARMACEUTICALS CO (JP) | 2024-05-08 | — | — | EP | claimed |
| EP-3146977-B1 | TFPI INHIBITORS AND METHODS OF USE | TAKEDA PHARMACEUTICALS CO (JP) | 2024-05-08 | — | — | EP | disclosed |
| US-11793855-B2 | TFPI inhibitors and methods of use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-24 | — | — | US | disclosed |
| US-10800816-B2 | TFPI inhibitors and methods of use | Baxalta GmbH (CH) | 2020-10-13 | — | — | US | disclosed |
| US-20190134147-A1 | TFPI INHIBITORS AND METHODS OF USE | Baxalta GmbH (CH) | 2019-05-09 | — | — | US | disclosed |
| EP-2827883-B1 | TFPI INHIBITORS AND METHODS OF USE | Baxalta GmbH (CH) | 2019-05-08 | — | — | EP | disclosed |
| US-10201586-B2 | TFPI inhibitors and methods of use | Baxalta GmbH (CH) | 2019-02-12 | — | — | US | disclosed |
| US-20180155399-A1 | TFPI INHIBITORS AND METHODS OF USE | Baxalta GmbH (CH) | 2018-06-07 | — | — | US | disclosed |
| US-9873720-B2 | TFPI inhibitors and methods of use | Baxalta GmbH (CH) | 2018-01-23 | — | — | US | disclosed |
| US-20170174727-A1 | TFPI INHIBITORS AND METHODS OF USE | Baxalta GmbH (CH) | 2017-06-22 | — | — | US | disclosed |
| EP-3146977-A1 | TFPI INHIBITORS AND METHODS OF USE | Baxalta GmbH (CH) | 2017-03-29 | — | — | EP | disclosed |
| US-9556230-B2 | TFPI inhibitors and methods of use | Baxalta GmbH (CH) | 2017-01-31 | — | — | US | disclosed |
| EP-2547355-B1 | TFPI INHIBITORS AND METHODS OF USE | Baxalta GmbH (CH) | 2017-01-11 | — | — | EP | disclosed |
| US-20150232514-A1 | TFPI INHIBITORS AND METHODS OF USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-20 | — | — | US | disclosed |
| US-9018167-B2 | TFPI inhibitors and methods of use | BAXTER INTERNATIONAL INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-8962563-B2 | TFPI inhibitors and methods of use | BAXTER INTERNATIONAL, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20130259863-A1 | TFPI INHIBITORS AND METHODS OF USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-10-03 | — | — | US | disclosed |
| US-20130252896-A1 | TFPI INHIBITORS AND METHODS OF USE | BAXTER HEALTHCARE SA (CH) | 2013-09-26 | — | — | US | disclosed |
| US-8450275-B2 | TFPI inhibitors and methods of use | BAXTER INTERNATIONAL INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20120028901-A1 | TFPI INHIBITORS AND METHODS OF USE | BAXTER INTERNATIONAL INC. (US) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028901-A1 | TFPI INHIBITORS AND METHODS OF USE | TFPI, TFPI2, F3 | OTC 3746/4885GSR 4809/4885DDAH1 2114/4885 |
| US-20170174727-A1 | TFPI INHIBITORS AND METHODS OF USE | TFPI, TFPI2, F13B | OTC 3293/4885GSR 4806/4885DDAH1 2089/4885 |
| US-20180155399-A1 | TFPI INHIBITORS AND METHODS OF USE | TFPI, TFPI2, F13B | OTC 3293/4885GSR 4806/4885DDAH1 2089/4885 |
| US-20150232514-A1 | TFPI INHIBITORS AND METHODS OF USE | TFPI, TFPI2, F3 | OTC 3746/4885GSR 4809/4885DDAH1 2114/4885 |
| US-20130259863-A1 | TFPI INHIBITORS AND METHODS OF USE | TFPI, TFPI2, F3 | OTC 3746/4885GSR 4809/4885DDAH1 2114/4885 |
| US-20130252896-A1 | TFPI INHIBITORS AND METHODS OF USE | TFPI, TFPI2, F13B | OTC 3293/4885GSR 4806/4885DDAH1 2089/4885 |
| US-10201586-B2 | TFPI inhibitors and methods of use | TFPI, TFPI2, F3 | OTC 3759/4885GSR 4808/4885DDAH1 2125/4885 |
| US-11793855-B2 | TFPI inhibitors and methods of use | TFPI, TFPI2, F3 | OTC 3759/4885GSR 4808/4885DDAH1 2125/4885 |
| US-10800816-B2 | TFPI inhibitors and methods of use | TFPI, TFPI2, F13B | OTC 3293/4885GSR 4806/4885DDAH1 2089/4885 |
| US-20190134147-A1 | TFPI INHIBITORS AND METHODS OF USE | TFPI, TFPI2, F3 | OTC 3759/4885GSR 4808/4885DDAH1 2125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.